Orally-active angiotensin-converting enzyme inhibitors are rapidly establishing themselves
in the therapy of hypertension and congestive heart failure. Concerted efforts in a number of …

The discovery that bradykinin (BK) is a potent vasodilator which also enhances vascular
permeability was made as early as 1953 (see Rocha e Silva, 1964). The observations made …

The introduction of captopril-the first orally active inhibitor of angiotensin converting enzyme-
into clinical medicine has been an example of skilled, purposeful pharmacological …

The primary purpose of this review is to summarize new developments in the area of
inhibitors of the renin-angiotensin system. Specifically, inhibitors of the two main enzymes …

The cardiovascular system is under the control and regulation of the autonomic nervous
system. While effector organs of the cardiovascular system (heart, vasculature, kidneys) …

Angiotensin converting enzyme (ACE) inhibitors have emerged as a revolution in
antihypertensive therapy. Introduction of captopril, the first rationally designed ACE inhibitor …

Decades of peptide research have created a wide variety of biomedical polypeptides:
hormones, neurotransmitters, antigenic protein fragments, synthetic peptides, enzyme …

I, 1977 captopril (SQ. 14225 D-2 methyl-3 mercapto-propanoyl-L-proline) which acts to
inhibit the angiotensin-converting enzyme" was introduced as a new orally active …

Angiotensin converting enzyme inhibitors in the treatment of hypertension: Efficacy, metabolic
effects and side effects Page 1 Cardiovascular Drugs and Therapy 1:9-13, 1987 © Martinus …

Abstract In acid-media ([H+]= 0.01–0.06 M), each of the thiol compounds, D-penicillamine
(PEN, LPH2) and captopril (CAP, LCH2) exist in several proton-dependent forms which can …